Intent To Grant an Exclusive License for a U.S. Government-Owned Invention

In accordance with 35 U.S.C. 209(e), and 37 CFR 404.7(a)(1)(i), announcement is made of the intent to grant an exclusive, revocable license, to U.S. Provisional Patent No. 62/ 086,355, filed December 2, 2014, entitled, ``Novel Regimens of Tafenoquine For Prevention of Malaria in Malaria-Na[iuml]ve Subjects,'' U.S. Patent No. 6,479,660, issued November 12, 2002, entitled, ``Process for the Preparation of Anti-Malarial Drugs,'' and U.S. Patent No. 7,145,014, issued December 5, 2006, entitled ``Process for the Preparation of Quinoline Derivatives.'' The intended licensee is 60[deg] Pharmaceuticals, LLC, with its principal place of business at 1025 Connecticut Ave. NW., Suite 1000, Washington, DC 20036.